β-blocker therapy for infantile hemangioma

References

• Richter GT, Friedman AB. Hemangiomas and vascular malformations: current theory and management. Int J Pediatr. 2012;2012:645678.
   PubMedGoogle Scholar
• Léauté‐Labrèze C, Prey S, Ezzedine K. Infantile haemangioma: part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities. J Eur Acad Dermatol Venereol. 2011;25(11):1245–1253.
   PubMed Web of Science ®Google Scholar
• Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69(3):412–422.
   PubMed Web of Science ®Google Scholar
• *Smithson SL, Rademaker M, Adams S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Australas J Dermatol. 1982;69(3):412–420. .
   Google Scholar
• Tan BH, Leadbitter P, Aburn N, et al. Steroid therapy for problematic proliferating haemangioma. N Z Med J. 2011;124:57–65.
   PubMedGoogle Scholar
• *Itinteang T, Withers AH, Leadbitter P, et al. Pharmacologic therapies for infantile hemangioma: is there a rational basis? Plast Reconstr Surg. 2011;128(2):499–507.
   PubMed Web of Science ®Google Scholar
• Léauté-Labrèze C, De La Roque ED, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–2651.
   PubMed Web of Science ®Google Scholar
• Bigorre M, Van Kien AK, Valette H. Beta-blocking agent for treatment of infantile hemangioma. Plast Reconstr Surg. 2009;123(6):195–196.
   Web of Science ®Google Scholar
• Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855–865.
   PubMed Web of Science ®Google Scholar
• Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1):e20183475.
   PubMed Web of Science ®Google Scholar
• Torres EB, Wittel JB, van Esso Arbolave DL, et al. Spanish consensus on infantile haemangioma. An Pediatr (Barc). 2016;85(5):256–265.
   PubMed Web of Science ®Google Scholar
• Yang H, Hu DL, Shu Q, et al. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies. World J Pediatr. 2019;15(6):546–558.
   PubMed Web of Science ®Google Scholar
• Moyakine AV, Kerstjens JM, Spillekom-van Koulil S, et al. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years. J Am Acad Dermatol. 2016;75(1):59–63.
   PubMed Web of Science ®Google Scholar
• Pope E, Chakkittakandiyil A, Lara‐Corrales I, et al. Expanding the therapeutic repertoire of infantile haemangiomas: cohort‐blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013;168(1):222–224.
   PubMed Web of Science ®Google Scholar
• Randhawa HK, Sibbald C, Garcia Romero MT, et al. Oral nadolol for the treatment of infantile hemangiomas: a single‐institution retrospective cohort study. Pediatr Dermatol. 2015;32(5):690–695.
   PubMed Web of Science ®Google Scholar
• Bernabeu‐Wittel J, Narváez‐Moreno B, de la Torre‐García JM, et al. Oral nadolol for children with infantile hemangiomas and sleep disturbances with oral propranolol. Pediatr Dermatol. 2015;32(6):853–857.
   PubMed Web of Science ®Google Scholar
• Wang Q, Xiang B, Chen S, et al. Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. Australas J Dermatol. 2019;60(3):181–185.
   PubMed Web of Science ®Google Scholar
• Abarzúa-Araya Á, Navarrete-Dechent CP, Heusser F, et al. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol. 2014;70(6):1045–1049.
   PubMed Web of Science ®Google Scholar
• Gumina ME, Yan AC. Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas. Pediatr Dermatol. 2019;36(4):556–557.
   PubMed Web of Science ®Google Scholar
• de Graaf M, Raphael MF, Breugem CC, et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. J Plast Reconstr Aesthet Surg. 2013;66(12):1732–1740.
   PubMed Web of Science ®Google Scholar
• Ashraf R, Mahajan R, Abas M, et al. Comparing the clinical, radiologic and biochemical effectiveness of atenolol and propranolol in the treatment of infantile hemangioma - a randomized controlled Trial.2019; [cited 2019 Nov 14]. Available from: https://ssrn.com/abstract=3353380
   Google Scholar
• Ji Y, Wang Q, Chen S, et al. Oral atenolol therapy for proliferating infantile hemangioma: a prospective study. Medicine (Baltimore). 2016;95(24):e3908.
   PubMed Web of Science ®Google Scholar
• Blanchet C, Nicollas R, Bigorre M, et al. Management of infantile subglottic hemangioma: acebutolol or propranolol? Int J Pediatr Otorhinolaryngol. 2010;74(8):959–961.
   PubMed Web of Science ®Google Scholar
• Ovadia SA, Landy DC, Cohen ER, et al. Local administration of beta-blockers for infantile hemangiomas: a systematic review and meta-analysis. Ann Plast Surg. 2015;74(2):256–262. .
   PubMed Web of Science ®Google Scholar
• Abdel Wahab SM, Almetaher HA, Fayad H, et al. Oral versus topical propranolol for management of superficial infantile hemangiomas. Ann Paediatr Surg. 2017;13(1):1–7.
   Web of Science ®Google Scholar
• Chan H, McKay C, Adams S, et al. RCT of timolol maleate gel for superficial infantile hemangiomas in 5-to 24-week-olds. Pediatrics. 2013;131(6):1739–1747.
   Web of Science ®Google Scholar
• Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel‐forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2012;29(1):28–31.
   PubMed Web of Science ®Google Scholar
• Weibel L, Barysch MJ, Scheer HS, et al. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol. 2016;33(2):184–190.
   PubMed Web of Science ®Google Scholar
• ST T, Itinteang T, DJ D, et al. Treatment of infantile haemangioma with captopril. Br J Dermatol. 2012;167(3):619–624.
   PubMed Web of Science ®Google Scholar
• Zaher H, Rasheed H, El-Komy MM, et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. J Am Acad Dermatol. 2016;74(3):499–505.
   PubMed Web of Science ®Google Scholar
• Christou EM, Wargon O. Effect of captopril on infantile haemangiomas: a retrospective case series. Australas J Dermatol. 2012;53(3):216–218.
   PubMed Web of Science ®Google Scholar
• Storch C, Hoeger P. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163(2):269–274.
   PubMed Web of Science ®Google Scholar
• Chim H, Armijo BS, Miller E, et al. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann Surg. 2012;256(1):146–156.
   PubMed Web of Science ®Google Scholar
• *Sasaki M, North PE, Elsey J, et al. Propranolol exhibits activity against hemangiomas independent of beta blockade. NPJ Precis Oncol. 2019;3:27.
   PubMed Web of Science ®Google Scholar
• Smith SKS, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim. 2002;38(5):298–304.
   PubMed Web of Science ®Google Scholar
• Itinteang T, Marsh R, Davis PF, et al. Angiotensin II causes cellular proliferation in infantile haemangioma via angiotensin II receptor 2 activation. J Clin Pathol. 2015;68(5):346–350. .
   PubMed Web of Science ®Google Scholar
• Itinteang T, Brasch HD, Tan ST, et al. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg. 2011;64(6):759–765.
   PubMed Web of Science ®Google Scholar
• van Schaijik B, Tan ST, Marsh RW, et al. Expression of (pro)renin receptor and its effect on endothelial cell proliferation in infantile hemangioma. Pediatr Res. 2019;86(2):202–207.
   PubMed Web of Science ®Google Scholar
• Tan CE, Itinteang T, *Leadbitter P, et al. Low-dose propranolol regimen for infantile haemangioma. J Paediatr Child Health. 2015;51(4):419–424.
   PubMed Web of Science ®Google Scholar
• Sulzberger L, Baillie R, Itinteang T, et al. Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma. J Plast Reconstr Aesthet Surg. 2016;69(3):381–386.
   PubMed Web of Science ®Google Scholar
• Itinteang T, Tan ST, Brasch HD, et al. Infantile haemangioma expresses embryonic stem cell markers. J Clin Pathol. 2012;65(5):394–398.
   PubMed Web of Science ®Google Scholar
• Itinteang T, Tan ST, Brasch H, et al. Primitive mesodermal cells with a neural crest stem cell phenotype predominate proliferating infantile haemangioma. J Clin Pathol. 2010;63(9):771–776.
   PubMed Web of Science ®Google Scholar
• Itinteang T, Tan ST, Brasch H, et al. Haemogenic endothelium in infantile haemangioma. J Clin Pathol. 2010;63(11):982–986.
   PubMed Web of Science ®Google Scholar
• Xu D, T MO, Shartava A, et al. Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model. J Hematol Oncol. 2011;4(54):1–12.
   PubMedGoogle Scholar
• Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood. 2004;103(4):1373–1375.
   PubMed Web of Science ®Google Scholar
• Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest. 2008;118(7):2592–2599.
   PubMed Web of Science ®Google Scholar
• Itinteang T, Vishvanath A, DJ D, et al. Mesenchymal stem cells in infantile haemangioma. J Clin Pathol. 2011;64(3):232–236.
   PubMed Web of Science ®Google Scholar
• Yu Y, Fuhr J, Boye E, et al. Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells. 2006;24(6):1605–1612.
   PubMed Web of Science ®Google Scholar
• Itinteang T, Tan S, Brasch H, et al. Primitive erythropoiesis in infantile haemangioma. Br J Dermatol. 2011;164(5):1097–1100.
   PubMed Web of Science ®Google Scholar
• *Itinteang T, Withers AH, Davis PF, et al. Biology of infantile hemangioma. Front Surg. 2014;1:1–10.
   Google Scholar
• Itinteang T, Tan ST, Guthrie S, et al. A placental chorionic villous mesenchymal core cellular origin for infantile haemangioma. J Clin Pathol. 2011;64(10):870–874.
   PubMed Web of Science ®Google Scholar
• North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol. 2001;137(5):559–570.
   PubMedGoogle Scholar
• North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31(1):11–22.
   PubMed Web of Science ®Google Scholar
• Winter PR, Itinteang T, Leadbitter P, et al. PHACE syndrome - clinical features, aetiology and management. Acta Paediatr. 2016;105(2):145–153.
   PubMed Web of Science ®Google Scholar
• Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010;157(5):795–801.
   PubMed Web of Science ®Google Scholar
• Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29(9):1675–1684.
   PubMed Web of Science ®Google Scholar
• Fyhrquist F, Saijonmaa O. Renin‐angiotensin system revisited. J Intern Med. 2008;264(3):224–236.
   PubMed Web of Science ®Google Scholar
• *Munro MJ, Wickremesekera AC, Davis PF, et al. Renin-angiotensin system and cancer: a review. Integr Cancer Sci Ther. 2017;4(2):1–6.
   Google Scholar
• Papali’i-Curtin JC, Brasch HD, van Schaijik B, et al. Expression of components of the Renin-Angiotensin system in pyogenic granuloma. Front Surg. 2019;6:1–8.
   PubMed Web of Science ®Google Scholar
• Siljee S, Keane E, Marsh R, et al. Expression of the components of the renin-angiotensin system in venous malformation. Front Surg. 2016;3:24.
   PubMed Web of Science ®Google Scholar
• Tan EMS, Brasch HD, Davis PF, et al. Embryonic stem cell-like population within venous malformation expresses the Renin-Angiotensin system. Plast Reconstr Surg Glob Open. 2019;7(4):e2170.
   PubMedGoogle Scholar
• Kilmister EJ, Paterson C, Brasch HD, et al. The role of the renin-angiotensin system and vitamin d in keloid disorder - a review. Front Surg. 2019;6:1–12.
   PubMed Web of Science ®Google Scholar
• On N, Koh SP, Brasch HD, et al. Embryonic stem cell-like population in Dupuytren’s disease expresses components of the renin-angiotensin system. Plast Reconstr Surg Glob Open. 2017;5(7):e1422.
   PubMedGoogle Scholar
• Humphries H, Brasch HD, van Schaijik B, et al. Expression of components of the renin-angiotensin system by the embryonic stem cell–like population within keloid lesions. Plast Reconstr Surg. 2019;144(2):372–384.
   PubMed Web of Science ®Google Scholar
• Shivapathasundram G, Wickremesekera AC, Brasch HD, et al. Expression of components of the renin-angiotensin system by the putative stem cell population within WHO grade I meningioma. Front Surg. 2019;6:23.
   PubMed Web of Science ®Google Scholar
• Featherston T, Yu HH, Dunne JC, et al. Cancer stem cells in moderately differentiated buccal mucosal squamous cell carcinoma express components of the renin-angiotensin system. Front Surg. 2016;3:1–8.
   PubMed Web of Science ®Google Scholar
• Ram RS, Brasch HD, Dunne JC, et al. Cancer stem cells in moderately differentiated lip squamous cell carcinoma express components of the renin-angiotensin system. Front Surg. 2017;4:1–8.
   PubMed Web of Science ®Google Scholar
• Itinteang T, Dunne JC, Chibnall AM, et al. Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma express components of the renin–angiotensin system. J Clin Pathol. 2016;69(10):942–945.
   PubMed Web of Science ®Google Scholar
• Bradshaw AR, Wickremesekera AC, Brasch HD, et al. Glioblastoma multiforme cancer stem cells express components of the renin-angiotensin system. Front Surg. 2016;3:1–8.
   PubMed Web of Science ®Google Scholar
• Narayanan A, Wickremesekera SK, Van Schaijik B, et al. Cancer stem cells in liver metastasis from colon adenocarcinoma express components of the renin-angiotensin system. J Cancer Metastasis Treat. 2019;5(36):1–11.
   Google Scholar
• Wickremesekera AC, Brasch HD, Lee VM, et al. Cancer stem cell subpopulations in metastatic melanoma to the brain express components of the renin-angiotensin system. J Cancer Metastasis Treat. 2019;5:62.
   Google Scholar
• Nallaiah S, Lee VMY, Brasch HD, et al. Cancer stem cells within moderately differentiated head and neck cutaneous squamous cell carcinoma express components of the renin-angiotensin system. J Plast Reconstr Aesthet Surg. 2019;72(9):1484–1493.
   PubMed Web of Science ®Google Scholar
• Koh SP, Wickremesekera AC, Brasch HD, et al. Expression of cathepsins B, D, and G in isocitrate dehydrogenase-wildtype glioblastoma. Front Surg. 2017;4:1–9.
   PubMed Web of Science ®Google Scholar
• Balakumar P, Jagadeesh G. Potential cross-talk between (pro) renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders. Hypertens Res. 2011;34(11):1161–1170.
   PubMed Web of Science ®Google Scholar
• Fiselier T, Lijnen P, Monnens L, et al. Levels of renin, angiotensin I and II, angiotensin-converting enzyme and aldosterone in infancy and childhood. Eur J Pediatr. 1983;141(1):3–7.
   PubMed Web of Science ®Google Scholar
• Pipkin FB, Smales O, O’Callaghan M. Renin and angiotensin levels in children. Arch Dis Child. 1981;56(4):298–302.
   PubMed Web of Science ®Google Scholar
• Dillon M, Ryness JM. Plasma renin activity and aldosterone concentration in children. Br Med J. 1975;4:316–319.
   PubMedGoogle Scholar
• Itinteang T, Chudakova DA, Dunne JC, et al. Expression of cathepsins B, D, and G in infantile hemangioma. Front Surg. 2015;2:1–8.
   PubMed Web of Science ®Google Scholar
• Tan ST, Wallis RA, He Y, et al. Mast cells and hemangioma. Plast Reconstr Surg. 2004;113(3):999–1011.
   PubMed Web of Science ®Google Scholar
• Tan EM, Chudakova DA, Davis PF, et al. Characterisation of subpopulations of myeloid cells in infantile haemangioma. J Clin Pathol. 2015;68(7):571–574.
   PubMed Web of Science ®Google Scholar
• Hermans D, Bauland C, Zweegers J, et al. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. Br J Dermatol. 2013;168(4):837–843.
   PubMed Web of Science ®Google Scholar
• Ji Y, Chen S, Xu C, et al. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015;172(1):24–32.
   PubMed Web of Science ®Google Scholar
• Itinteang T, Davis P, Tan S. Treatment of infantile hemangioma with an ACE inhibitor: a paradigm shift. In: Onuigbo MA, editor. ACE Inhibitors. Vol. 2. New York: Nova Science Publishers, Inc; 2014. p. 323–332.
   Google Scholar
• de Jong S, Itinteang T, Withers AH, et al. Does hypoxia play a role in infantile hemangioma? Arch Dermatol Res. 2016;308(4):219–227.
   PubMed Web of Science ®Google Scholar
• Pagé EL, Robitaille GA, Pouysségur J, et al. Induction of hypoxia-inducible factor-1α by transcriptional and translational mechanisms. J Biol Chem. 2002;277(50):48403–48409.
   PubMed Web of Science ®Google Scholar
• Overman J, Fontaine F, Wylie-Sears J, et al. R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. Elife. 2019;8:e43026.
   PubMed Web of Science ®Google Scholar
• Price CJ, Lattouf C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol. 2011;147(12):1371–1376.
   PubMedGoogle Scholar
• Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatr. 2013;131(1):128–140.
   PubMed Web of Science ®Google Scholar
• Raphael MF, Breugem CC, Vlasveld FA, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: a cohort study. J Am Acad Dermatol. 2015;72(3):465–472.
   PubMed Web of Science ®Google Scholar
• El Ezzi O, Hohlfeld J. de Buys Roessingh A. Propranolol in infantile haemangioma: simplifying pretreatment monitoring. Swiss Med Wkly. 2014;144:w13943.
   PubMed Web of Science ®Google Scholar
• Püttgen KB. Diagnosis and management of infantile hemangiomas. Pediatr Clin N Am. 2014;61(2):383–402.
   PubMed Web of Science ®Google Scholar
• Kim KH, Choi TH, Choi Y, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA Dermatol. 2017;153(6):529–536.
   PubMed Web of Science ®Google Scholar
• Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013;30(2):182–191.
   PubMed Web of Science ®Google Scholar
• *Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–746.
   PubMed Web of Science ®Google Scholar
• Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259–e66.
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Penington AJ, Bekhor PS, et al. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health. 2012;48(10):902–906.
   PubMed Web of Science ®Google Scholar
• Horbach SER, van der Horst C, Blei F, et al. Development of an international core outcome set for peripheral vascular malformations: the OVAMA project. Br J Dermatol. 2018;178(2):473–481.
   PubMed Web of Science ®Google Scholar
• *Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016;137(4):e20151754.
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Crock CM, Penington AJ, et al. Prolonged tumour growth after treatment of infantile haemangioma with propranolol. Med J Aust. 2017;206(3):131.
   PubMed Web of Science ®Google Scholar
• Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138(4):e20160353.
   PubMed Web of Science ®Google Scholar
• Ji Y, Chen S, Wang Q, et al. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep. 2018;8(1):1–7.
   PubMedGoogle Scholar
• Droitcourt C, Kerbrat S, Rault C, et al. Safety of oral propranolol for infantile hemangioma. Pediatrics. 2018;141(6):e20173783.
   PubMed Web of Science ®Google Scholar
• Chang L, Ye X, Qiu Y, et al. Is propranolol safe and effective for outpatient use for infantile hemangioma? A prospective study of 679 cases from one center in China. Ann Plast Surg. 2016;76(5):559–563.
   PubMed Web of Science ®Google Scholar
• Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. Br J Dermatol. 2015;172(1):13–23.
   PubMed Web of Science ®Google Scholar
• Propranolol. In: DRUGDEX Evaluations [ database on the Internet]. Greenwood Village (CO): Truven Health Analytics; 2020 [2020 January 27]. Available from: https://www.micromedexsolutions.com.
   Google Scholar
• McMahon P, Oza V, Frieden IJ. Topical timolol for infantile hemangiomas: putting a note of caution in “cautiously optimistic”. Pediatr Dermatol. 2012;29(1):127–130.
   PubMed Web of Science ®Google Scholar
• Temple ME, Nahata MC. Treatment of pediatric hypertension. Pharmacotherapy. 2000;20(2):140–150.
   PubMed Web of Science ®Google Scholar